- Jefferies analyst Andrew Tsai sets a new price target for NASDAQ:PRAX at $300, indicating a potential growth of approximately 70.69%.
- Promising results from experimental drug for movement disorders fuel optimism, potentially enhancing Praxis’s position in the healthcare sector.
- PRAX’s current trading price marks a significant increase, with a year-high of $205.89 and a substantial market capitalization of approximately $3.70 billion.
Praxis Precision Medicines, trading under NASDAQ:PRAX, is a company focused on developing treatments for central nervous system disorders. Recently, Andrew Tsai from Jefferies set a new price target for PRAX at $300, a significant increase from its current price of $175.76. This target suggests a potential growth of approximately 70.69%, reflecting optimism about the company’s future prospects.
The optimism surrounding PRAX is fueled by promising results from its experimental drug for movement disorders. The drug has shown improvement in daily functioning for patients in two late-stage trials, as highlighted by Reuters. This advancement could strengthen Praxis’s position in the healthcare and pharmaceuticals sector, potentially driving further interest from investors.
Currently, PRAX is trading at $176.01, marking a substantial increase of 206.90% with a change of $118.66. The stock has seen fluctuations today, with a low of $158 and a high of $205.89, the latter being its highest price in the past year. This volatility indicates active trading and interest in the stock.
PRAX’s market capitalization stands at approximately $3.70 billion, reflecting the company’s value in the market. The trading volume today is 11.48 million shares, suggesting significant investor activity. The stock’s lowest price for the year was $26.70, highlighting its impressive growth over the past months.
